CRISPR/Cas9 library screening uncovered CCT2 as a critical driver of acquired resistance to EGFR-targeted therapy by stabilizing TMX1 in non-small cell lung cancer.
CRISPR/Cas9 文库筛选发现 CCT2 是非小细胞肺癌中通过稳定 TMX1 而导致获得性 EGFR 靶向治疗耐药性的关键驱动因素。
期刊:Cell Death and Differentiation
影响因子:15.4
doi:10.1038/s41418-025-01600-w
Ke Zihao, Zhang Qi, Chen Xingyu, Jin Rongrong, Han Gaohua, Cao Qianhua, Zhu Ke, Wei Shihui, Chen Jiajin, Wang Qian, Zhang Meiling, Huang Weina, Li Kaimin, Xiong Kunlong, Lu Kaihua, Chen Ying, Cao Chao
